Study Details
Full Title
Protocol A092204, A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2819) (Cabo-Cemiplimab (REGN2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer (NCT06900595)
Principal Investigator
Diane
Reidy
Protocol Number
PRO00119543
NCT ID
NCT06900595
Phase
II
Enrollment Status
Open to Enrollment